Ataxia With Vitamin E Deficiency is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ataxia with Vitamin E Deficiency (AVED) is a rare autosomal recessive neurodegenerative disorder characterized by progressive cerebellar ataxia, peripheral neuropathy, and significantly reduced serum vitamin E levels. The disease results from mutations in the TTPA gene (alpha-tocopherol transfer protein), which impairs the body's ability to utilize and transport vitamin E.[1]
AVED is a hereditary ataxia that mimics Friedreich's ataxia in its clinical presentation but is potentially treatable with vitamin E supplementation. The condition was first described in 1981 and is estimated to affect approximately 1 in 500,000 individuals worldwide, though it may be underdiagnosed due to clinical overlap with other ataxias.[2]
¶ Genetics and Pathophysiology
AVED is caused by homozygous or compound heterozygous mutations in the TTPA gene located on chromosome 8q13.1. This gene encodes alpha-tocopherol transfer protein (α-TTP), which is responsible for incorporating alpha-tocopherol (the most active form of vitamin E) into very-low-density lipoprotein (VLDL) for distribution to tissues.[3]
More than 40 pathogenic variants have been identified in TTPA, including:
- Nonsense mutations
- Missense mutations
- Frameshift mutations
- Splice site mutations
The most common mutation varies by population, with the p.Lys197Asnfs*38 mutation being frequent in North African families.[4]
Vitamin E deficiency in AVED leads to:
- Increased oxidative stress - Alpha-tocopherol is a potent antioxidant that protects cell membranes from lipid peroxidation
- Neuronal damage - Particularly in cerebellar Purkinje cells and peripheral nerve axons
- Myelin degeneration - Demyelination of peripheral nerves and central nervous system pathways
The neuropathology shows:
- Cerebellar atrophy, especially of the vermis
- Loss of Purkinje cells
- Peripheral axonal neuropathy
- Dorsal column degeneration
[5]
| Symptom |
Onset Age |
Frequency |
| Progressive ataxia |
4-20 years |
100% |
| Areflexia (absent reflexes) |
Childhood |
90% |
| Distal weakness |
5-15 years |
80% |
| Dysarthria (slurred speech) |
5-18 years |
85% |
| Head titubation |
Childhood |
70% |
| Reduced proprioception |
Childhood |
75% |
- Scoliosis - Develops in approximately 50% of patients
- Cardiomyopathy - Less common than in Friedreich's ataxia
- Retinitis pigmentosa - Can occur in advanced cases
- Cognitive impairment - Usually mild, but some patients show intellectual disability
- Movement disorders - Including dystonia and tremor in some cases
[6]
The progression of AVED follows a characteristic pattern:
- Early stage (ages 4-10): Mild ataxia, often misdiagnosed as clumsy child syndrome
- Middle stage (ages 10-20): Progressive gait disturbance, loss of reflexes, development of dysarthria
- Late stage (ages 20-30): Severe disability, wheelchair dependence in many patients
- Advanced stage: Complete loss of ambulation in approximately 50% by age 30
[7]
Diagnosis is based on:
- Progressive cerebellar ataxia starting before age 20
- Reduced or absent reflexes
- Serum vitamin E level < 5 μg/mL (normal: 5-20 μg/mL)
- TTPA gene mutation confirmation
- Exclusion of other causes of ataxia
AVED must be distinguished from:
- Friedreich's ataxia (similar phenotype but with cardiomyopathy)
- Other hereditary ataxias (SCA, ataxia-telangiectasia)
- Acquired vitamin E deficiency (malabsorption, liver disease)
- Vitamin B12 deficiency
| Test |
Finding |
| Serum vitamin E |
Markedly reduced (< 5 μg/mL) |
| Serum cholesterol |
Usually normal |
| Brain MRI |
Cerebellar atrophy, especially vermis |
| Nerve conduction studies |
Axonal peripheral neuropathy |
| Genetic testing |
TTPA pathogenic variants |
| ECG |
Usually normal (differs from Friedreich's) |
High-dose vitamin E supplementation is the cornerstone of treatment:
- Dosage: 800-1200 IU/day of alpha-tocopherol
- Form: Natural d-alpha-tocopherol is preferred over synthetic
- Response: Stabilization or mild improvement in most patients
- Early treatment is critical - best outcomes when started before significant neurological damage
- Physical therapy: Maintains mobility and prevents contractures
- Occupational therapy: Adaptive devices for daily activities
- Speech therapy: For dysarthria management
- Orthopedic interventions: For scoliosis and foot deformities
- Cardiac monitoring: Even though cardiomyopathy is less common
With early diagnosis and consistent treatment:
- Disease progression can be halted or significantly slowed
- Many patients maintain ambulation into adulthood
- Quality of life is substantially improved
- Without treatment, progressive disability leads to wheelchair dependence
[8]
- Prevalence: Approximately 1 in 500,000
- Inheritance: Autosomal recessive
- Geographic distribution: Worldwide, with higher prevalence in regions with consanguinity
- Ethnicity: More common in North African, Mediterranean, and Middle Eastern populations
- Gender distribution: Equal between males and females
Several clinical trials are investigating:
- Optimized vitamin E dosing regimens
- Gene therapy approaches for TTPA
- Antioxidant adjunctive therapies
- Biomarkers for early detection and treatment response
TTPA knockout mice recapitulate the human disease phenotype and are used to study:
- Vitamin E transport mechanisms
- Neuroprotective interventions
- Gene therapy delivery
The study of Ataxia With Vitamin E Deficiency has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Di Donato I, Bianchi S, Federico A. Ataxia with vitamin E deficiency: update of a case. J Neurol. 2010;257(7):1173-1174. PMID:20213361
- Masri A, Al MSA. Ataxia with vitamin E deficiency in the Middle East. Mov Disord. 2009;24(3):421-426. PMID:19053056
- Ouahchi K, Arita M, Kayden H, et al. Ataxia and peripheral neuropathy are associated with a mutation in a gene encoding alpha-tocopherol transfer protein. Nat Genet. 1995;11(4):381-383. PMID:7493015
- Hentati A, El-Euch G, Bouhlal Y, Amri R. Ataxia with vitamin E deficiency: clinical, neurophysiological and molecular study. J Neurol Sci. 2009;285(1-2):125-128. PMID:19589686
- Koenig M, Durr A, Brice A. Ataxia with vitamin E deficiency: a treatable hereditary disorder. Rev Neurol (Paris). 2003;159(5):511-518. PMID:12805023
- Mariotti C, Gellera C, Rimoldi M, et al. Ataxia with vitamin E deficiency: clinical features and molecular genetics. J Neurol Neurosurg Psychiatry. 2004;75(4):617-620. PMID:15026515
- Schuelke M. Ataxia with Vitamin E Deficiency. In: Adam MP, et al., eds. GeneReviews. University of Washington; 2009. Updated 2020.
- Gabsi S, Gouider-Khouja N, Belal S, et al. Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. Eur J Neurol. 2001;8(5):477-481. PMID:11554914